Zacks: Analysts Anticipate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Post Earnings of -$1.69 Per Share

Analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating) will post ($1.69) earnings per share for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Alnylam Pharmaceuticals’ earnings, with estimates ranging from ($2.02) to ($1.13). Alnylam Pharmaceuticals posted earnings per share of ($1.61) during the same quarter last year, which suggests a negative year-over-year growth rate of 5%. The business is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Alnylam Pharmaceuticals will report full year earnings of ($6.94) per share for the current financial year, with EPS estimates ranging from ($8.52) to ($5.19). For the next year, analysts anticipate that the business will post earnings of ($3.22) per share, with EPS estimates ranging from ($8.73) to $0.35. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) last issued its earnings results on Thursday, April 28th. The biopharmaceutical company reported ($2.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.84) by ($0.16). The business had revenue of $186.90 million during the quarter, compared to the consensus estimate of $242.82 million. Alnylam Pharmaceuticals had a negative net margin of 101.46% and a negative return on equity of 121.90%. The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period last year, the business posted ($1.71) EPS.

Several brokerages have commented on ALNY. Chardan Capital reiterated a “buy” rating and set a $200.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, February 11th. Guggenheim raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $170.00 target price on the stock in a research note on Thursday, February 3rd. Oppenheimer restated an “outperform” rating and set a $205.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 6th. Bank of America reaffirmed a “buy” rating and issued a $211.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 3rd. Finally, StockNews.com assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $219.76.

Shares of ALNY stock opened at $139.05 on Tuesday. Alnylam Pharmaceuticals has a 52-week low of $125.00 and a 52-week high of $212.00. The stock has a market cap of $16.79 billion, a PE ratio of -18.56 and a beta of 0.85. The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.91 and a current ratio of 4.04. The firm’s 50 day moving average price is $160.12 and its two-hundred day moving average price is $165.56.

In other news, Director Steven M. Paul sold 15,000 shares of the business’s stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $170.69, for a total value of $2,560,350.00. Following the sale, the director now directly owns 1,000 shares in the company, valued at $170,690. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.40% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in ALNY. UMB Bank N A MO bought a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at $28,000. FSB Premier Wealth Management Inc. bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $30,000. KRS Capital Management LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $33,000. Achmea Investment Management B.V. bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $35,000. Finally, HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $37,000. Institutional investors own 92.39% of the company’s stock.

Alnylam Pharmaceuticals Company Profile (Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Read More

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.